Skip to main content

Table 1 Baseline routine and specific laboratory investigations of the studied groups

From: Hepatitis C core antigen: a simple predictive marker for treatment response to the new direct-acting antiviral drugs in chronic HCV Egyptian patients

Lab investigations

Total cases (No. = 280)

Test of significance

P value

Group I (No. = 140)

Group II (No. = 80)

Group III (No. = 60)

Mean ± SD

Mean ± SD

Mean ± SD

ALT (IU/ml)

58.6 ± 7.8

75.0 ± 20.6

122.0 ± 66.4

Kruskal-Wallis test = 17.6

< 0.001**

AST(IU/ml)

44.1 ± 13.3

65.0 ± 23.3

114.2 ± 67.6

Kruskal-Wallis test = 17.14

< 0.001**

ALP (IU/ml)

29.8 ± 14.8

75.1 ± 24.4

134.8 ± 68.8

Kruskal-Wallis test = 21.24

< 0.001**

GGT (IU/ml)

12.7 ± 7.5

30.1 ± 10.8

63.3 ± 12.1

Kruskal-Wallis test = 20.14

< 0.001**

Total bilirubin (mg/dl)

1.1 ± 0.27

1.2 ± 0.84

1.8 ± 1.2

Kruskal-Wallis test = 0.73

0.69

Albumin (g/dl)

3.8 ± 0.54

3.7 ± 0.39

3.4 ± 0.37

ANOVA test = 0.85

0.44

PT (s)

14.5 ± 2.1

14.5 ± 1.6

14.9 ± 2.2

ANOVA test = 0.08

0.92

PT concentration (%)

86.3 ± 19.5

86.8 ± 9.5

84.9 ± 13.9

ANOVA test = 0.05

0.95

INR

1.2 ± 0.17

1.2 ± 0.15

1.2 ± 0.18

ANOVA test = 0.09

0.91

Hb (gm/dl)

13.6 ± 1.7

13.6 ± 1.3

12.8 ± 2.8

ANOVA test = 0.41

0.67

PLT (X103/mm)

186.2 ± 48.3

189.9 ± 57.4

157.0 ± 62.6

Kruskal-Wallis test = 1.60

0.45

Glucose (mg/dl)

92.9 ± 30.5

90.1 ± 25.6

98.2 ± 36.9

Kruskal-Wallis test = 0.16

0.92

Creatinine(mg/dl)

0.81 ± 0.12

0.81 ± 0.09

0.83 ± 0.13

ANOVA test = 0.88

0.92

Urea (mg/dl)

35.0 ± 10.9

44.5 ± 9.1

39.5 ± 11.3

ANOVA test = 2.08

0.15